{"entity":{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","aka":[],"tldr":"A PET scan that shows which breast cancer deposits still have oestrogen receptors, helping decide whether hormone therapy will work when biopsy is impractical.","summary":"Fluoroestradiol F-18 is a PET radiotracer in which 18F-labelled oestradiol binds oestrogen receptor alpha, imaging ER expression across every lesion in the body in a single non-invasive scan. It was approved in the US in May 2020 as an adjunct to biopsy for detecting ER-positive lesions in recurrent or metastatic breast cancer, and entered NCCN guidelines in 2024. It is used when biopsy is impractical or when lesions may have lost ER, because it predicts endocrine responsiveness and reveals heterogeneous receptor loss that a single biopsy would miss. It also serves as a pharmacodynamic tool in trials of ER degraders, measuring receptor occupancy, and is under study in ER-positive ovarian and endometrial cancers. Uptake in the liver limits assessment of hepatic metastases. FES PET tells the oncologist whether hormone therapy still has a target.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Fluoroestradiol_F-18","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cerianna"}],"tags":["gap-fill","diagnostic"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["pet","pet-ct"],"targets":["estrogen-receptor"],"drugs":[],"companies":["ge-healthcare"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04692103","nct02398773","nct06260033"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Cerianna","modality":"PET radiotracer (oestrogen receptor ligand)","mechanism":"18F-labelled oestradiol binds oestrogen receptor alpha, imaging ER expression across all lesions non-invasively.","approvals":[{"region":"US","year":2020,"indication":"Detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fluoroestradiol-f18/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/"}],"company":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/"}],"trial":[{"id":"nct04883814","kind":"trial","name":"18F-fluoroestradiol (FES) PET/CT for Breast Cancer","route":"/trials/nct04883814/"},{"id":"nct02398773","kind":"trial","name":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","route":"/trials/nct02398773/"},{"id":"nct04692103","kind":"trial","name":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","route":"/trials/nct04692103/"},{"id":"nct06260033","kind":"trial","name":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","route":"/trials/nct06260033/"}],"roadmap":[{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/"}]}}